Focus:
Eye disease-focused Kodiak Sciences has entered into a funding agreement with Baker Bros Advisors, in which the investment firm will invest $225m into the company for royalty rights capped at...
Drug development company Chipscreen Biosciences’ oral subtype-selective histone deacetylase (HDAC) inhibitor, Epidaza (Chidamide), has secured approval in China for its second indication.
The US Food and Drug Administration (FDA) has granted tentative approval for Aleor Dermaceuticals’ Diclofenac sodium topical solution USP, 2% w / w to treat the pain of osteoarthritis of...
English-Swedish pharmaceutical and biopharmaceutical company AstraZeneca has secured the US Food and Drug Administration (FDA) priority review for Imfinzi (durvalumab) for the treatment of small cell lung cancer (SCLC).
US-based biopharmaceutical company Incyte has announced that the US Food and Drug Administration (FDA) accepted for priority review its New Drug Application (NDA) for pemigatinib as a treatment for patients...
The Chinese National Healthcare Security Administration (NHSA) has announced it has agreed an average 61% cut in prices of 70 top-selling drugs with large pharma manufacturers in exchange for inclusion...
European speciality pharmaceutical company Neuraxpharm Group has announced the launch of Neuraxpharm Portugal as part of an expansion of its operations in Southern Europe.
UK-based pharmaceutical company ImmuPharma has signed a licensing and development agreement with US-based Avion Pharmaceuticals for Lupuzor, a peptide therapeutic and a first-in class autophagy immunomodulator for auto-immune disease systemic...
Boehringer Ingelheim (Canada) has secured approval from Health Canada for its Ofev (nintedanib) to slow the rate of decline in patients suffering from systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Pfizer has announced the UK’s pricing regulator the National Institute of Health and Social Care (NICE) has recommended breast cancer drug Ibrance (palbociclib) for NHS use through the Cancer Drugs...
Go Top
